Nephrology
Review | Cardiorenal syndrome in the hospital
7 Aug, 2023 | 14:36h | UTCCardiorenal Syndrome in the Hospital – Clinical Journal of the American Society of Nephrology
Commentary on Twitter
The cardiorenal syndrome refers to a group of complex, bidirectional pathophysiological pathways involving dysfunction in both the heart and kidney. This Review focuses on the cardiorenal syndrome encountered in the hospital setting https://t.co/f05vpOPzCx pic.twitter.com/4Is5A2F1km
— CJASN (@CJASN) July 31, 2023
Review | Primary aldosteronism: a pragmatic approach to diagnosis and management
4 Aug, 2023 | 12:06h | UTCPrimary Aldosteronism: A Pragmatic Approach to Diagnosis and Management – Mayo Clinic Proceedings
KDIGO Conference | Managing the symptom burden associated with maintenance dialysis
4 Aug, 2023 | 12:02h | UTCNews Release: KDIGO Announces Publication of “Managing the Symptom Burden Associated with Maintenance Dialysis”
Commentary on Twitter
KDIGO is pleased to announce the publication of “Managing the Symptom Burden Associated with Maintenance Dialysis” in @Kidney_Int. The Conference Report is based on the KDIGO Symptom-Based Complications in Dialysis Controversies Conference in May 2022.
Read the News Release:… pic.twitter.com/AZKW9TPgxj
— KDIGO (@goKDIGO) August 1, 2023
M-A | Uncertain benefits of blood purification techniques in severe infection or sepsis
4 Aug, 2023 | 11:41h | UTC
International Study | Postoperative acute kidney injury affects one in five patients after major surgery
1 Aug, 2023 | 14:23h | UTC
Commentary on Twitter
? EPIS #AKI, epidemiology of major surgery associated acute kidney injury
➡️ > 10K pts, 1/5 develop PO-AKI: significant burden for health care worldwide!
⬆️ increasing severity of PO-AKI associated with progressive increase in adverse outcomes#FOAMcc
?️ https://t.co/Ps7N7zoMKP pic.twitter.com/gcxkve9OKV— Intensive Care Medicine (@yourICM) July 30, 2023
Novel therapeutics for management of lupus nephritis: what is next?
1 Aug, 2023 | 14:22h | UTCNovel Therapeutics for Management of Lupus Nephritis: What Is Next? – Kidney Medicine
Review | Revisiting resistant hypertension
1 Aug, 2023 | 14:16h | UTCRevisiting resistant hypertension: a comprehensive review – Internal Medicine Journal
Related: Resistant hypertension: A stepwise approach – Cleveland Clinic Journal of Medicine
Podcast: #390 Resistant Hypertension – The Curbsiders
Review | Updates on infectious and other complications in peritoneal dialysis
26 Jul, 2023 | 13:23h | UTCUpdates on Infectious and Other Complications in Peritoneal Dialysis: Core Curriculum 2023 – American Journal of Kidney Diseases (free for a limited period)
Related: ISPD Catheter-related Infection Recommendations: 2023 Update – Peritoneal Dialysis International
Commentary on Twitter
Updates on Infectious and Other Complications in Peritoneal Dialysis: Core Curriculum 2023 by Sana F. Khan, MD. https://t.co/DtYjfG79Yw (FREE) pic.twitter.com/lDeZcN3DJO
— AJKD (@AJKDonline) July 24, 2023
Cohort Study | Proton pump inhibitor use linked to increased fatigue in kidney transplant recipients
26 Jul, 2023 | 13:21h | UTC
Commentary on Twitter
Proton Pump Inhibitor Use, Fatigue, and Health-Related Quality of Life in Kidney Transplant Recipients: Results From the TransplantLines Biobank and Cohort Study https://t.co/DkDTvs9zjo #OpenAccess#VisualAbstract @umcg pic.twitter.com/XooY16qFVT
— AJKD (@AJKDonline) July 25, 2023
M-A | P2Y12 monotherapy after 1-3 months DAPT safely reduces bleeding in PCI patients with CAD and CKD
26 Jul, 2023 | 13:18h | UTCRelated:
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis – Nature Reviews Cardiology (if the link is paywalled, try this one)
Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial – JAMA Cardiology (link to abstract – $ for full-text)
M-A | Early initiation of renal replacement therapy fails to improve survival rates in AKI patients
25 Jul, 2023 | 13:46h | UTC
Systematic Review | Insufficient evidence for ACEi/ARB’s impact on early non-diabetic CKD
24 Jul, 2023 | 12:56h | UTC
Podcast | Hematuria pearls
19 Jul, 2023 | 14:19h | UTC#404 Hematuria with Dr. Derek Fine – The Curbsiders
RCT | Midodrine show promise as an alternative to albumin for the prevention of circulatory disturbance in paracentesis between 3 and 5 L
18 Jul, 2023 | 13:47h | UTC
M-A | First-line thiazide diuretics show reduced cardiovascular events, comparable mortality vs. other antihypertensive drugs
14 Jul, 2023 | 12:55h | UTC
AHA Statement | Indications, evaluation, and outcomes for dual heart-kidney and heart-liver transplantation
14 Jul, 2023 | 12:51h | UTC
Cohort Study | No significant difference in kidney risks between lithium and valproate therapies, but high lithium levels remain a concern
14 Jul, 2023 | 12:46h | UTC
RCT| Exercise during hemodialysis improves physical function in chronic kidney failure patients
13 Jul, 2023 | 13:01h | UTCExercise during Hemodialysis in Patients with Chronic Kidney Failure – NEJM Evidence
Retrospective Analysis | 18% of ICU patients develop sepsis-associated AKI, mostly stage 1, diagnosed by low urine output
12 Jul, 2023 | 13:39h | UTC
Commentary on Twitter
Fulminant myocarditis in #ICU
?short/long‑term prognosis
?clinical suspicion, initial recognition, differential diagnoses
?initial management & temporary #MCS: IABP #ECMO #Impella
?endomyocardial biopsy
?immunomodulatory therapies
?#FOAMcc @yourICM
?️https://t.co/JIGm4p0tv5 pic.twitter.com/o4RctuurEL— Intensive Care Medicine (@yourICM) July 11, 2023
Podcast | Untangling catheter associated UTIs
10 Jul, 2023 | 13:21h | UTC#402 Don’t Get Caught with a CAUTI – The Curbsiders
Review | Cardiovascular outcomes in patients with diabetes and kidney disease
7 Jul, 2023 | 16:13h | UTC
2023 ESH Guidelines for the management of arterial hypertension
3 Jul, 2023 | 14:34h | UTC
RCT | Substituting saline with balanced crystalloid solution reduces delayed graft function in kidney transplantation
30 Jun, 2023 | 14:56h | UTCSummary: The BEST-Fluids study was a pragmatic, multicentre, double-blind, randomized controlled trial carried out across 16 hospitals in Australia and New Zealand, aimed at comparing the use of balanced crystalloid solution (Plasma-Lyte 148) and saline in deceased donor kidney transplantation. The sample size comprised of 808 participants, who were either adults or children of any age, with the primary outcome defined as delayed graft function (DGF) occurring within 7 days post-transplantation.
Findings from the trial revealed that the balanced crystalloid group experienced less DGF than the saline group, with 121 out of 404 participants (30%) and 160 out of 403 participants (40%), respectively. This result yields an adjusted relative risk of 0.74 and an adjusted risk difference of 10.1%.
The study suggests that balanced crystalloid solution significantly reduces the incidence of DGF compared to saline. As no significant safety concerns were raised during the trial, the researchers recommend the use of balanced crystalloid solution as the standard-of-care intravenous fluid in deceased donor kidney transplantation. However, the study doesn’t indicate any significant differences in graft failure or mortality rates, which calls for further research.
Article: Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial – The Lancet (free registration required)
Clinical Trial Update | Equal long-term health and survival from restrictive vs. standard IV fluid therapy in septic shock patients
29 Jun, 2023 | 14:01h | UTCOriginal Study: RCT: A restrictive intravenous fluid strategy does not improve outcomes in ICU patients with septic shock.
Cohort Study | Younger adults with modest kidney function reductions show increased risk of adverse outcomes
28 Jun, 2023 | 13:14h | UTCSummary: This study was a retrospective, population-based cohort study exploring the implications of modest reductions in estimated glomerular filtration rate (eGFR) in young adults. The study was conducted on 8.7 million adult residents aged 18-65 years in Ontario, Canada, with no history of kidney disease. Data was collected from January 2008 to March 2021.
The research revealed that 18.0% of those aged 18-39, 18.8% of those aged 40-49, and 17.0% of those aged 50-65 had modestly reduced eGFR measurements specific to their age group. Adverse outcomes, including all-cause mortality, cardiovascular events, and kidney failure, were consistently higher by hazard ratio and incidence for ages 18-39 across all eGFR categories, compared to older groups. The hazard ratio for modest reductions (eGFR 70-80 mL/min/1.73m2) was found to be 1.42 for ages 18-39 years.
The findings suggest that even modest reductions in kidney function can significantly impact younger adults, necessitating frequent monitoring of kidney function in this demographic to prevent chronic kidney disease and its complications. It is noteworthy, however, that potential limitations of this study include possible misclassification of comorbidities, unmeasured confounding, and a lack of insight into the mechanism of these modest eGFR reductions.
News Release: Even a modest reduction in kidney function increases health risks in young adults – University of Ottawa